Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trantinterol hydrochloride
- Development stage
- Phase 4
- Lead developer
- Shenyang Pharmaceutical University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trantinterol hydrochloride (also known as SPFF) is a novel, orally active, ultra-long-acting beta-2 adrenergic receptor (ADRB2) agonist. Developed by Shenyang Pharmaceutical University and Shenyang Dashan Pharmaceutical, it is designed for the treatment of respiratory diseases, primarily asthma. Trantinterol hydrochloride acts as a potent bronchodilator by selectively binding to and activating beta-2 adrenergic receptors on airway smooth muscle cells, leading to muscle relaxation and improved airflow. In addition to its primary bronchodilatory mechanism, trantinterol has been shown to act as a noncompetitive inhibitor of P-glycoprotein (P-gp/ABCB1). It is currently in Phase III clinical development in China for the treatment of asthma.
- Other names
- tranteroltrantinterol
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on trantinterol hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trantinterol hydrochloride.